Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent
- 8 May 2001
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 1 (6) , 1199-1210
- https://doi.org/10.1016/s1567-5769(01)00056-x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTPImmunopharmacology, 1996
- PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. I. Suppression of the human mixed lymphocyte reaction (MLR)Inflammation Research, 1993
- Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955Biochemical Pharmacology, 1992
- Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitorInflammation Research, 1987
- Inhibition of Purine Nucleoside Phosphorylase by 8-Aminoguanosine: Selective Toxicity for T LymphoblastsScience, 1981
- Biochemistry of diseases of immunodevelopment.Annual Review of Biochemistry, 1981
- Allosteric regulation of calf thymus ribonucleoside diphosphate reductaseBiochemistry, 1979
- Abnormal Purine Metabolism and Purine Overproduction in a Patient Deficient in Purine Nucleoside PhosphorylaseNew England Journal of Medicine, 1976
- An abnormal form of purine nucleoside phosphorylase in a family with a child with severe defective T-cell-and normal B-cell immunityClinica Chimica Acta; International Journal of Clinical Chemistry, 1976
- NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITYThe Lancet, 1975